Background Immunotherapy focuses on selectively enhancing the host's immune response
against malignant disease. It has been investigated as an important treatment modality …

Simple Summary The human immune system is robustly equipped to keep unnatural cell
growth in check in the body to suppress cancer progression. However, the cells and …

Importance Geriatric (aged≥ 80 years) patients are historically underrepresented in cancer
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Cancer is a disease of older adults. The median age at cancer diagnosis is 66 years and
median age at cancer-related death is 72 years. 1 Older adults represent one of the fastest …

The number of older patients with cancer is increasing as a result of the ageing of Western
societies. Immune checkpoint inhibitors have improved cancer treatment and are associated …

PROBLEM STATEMENT: To define the Oncology Nursing Society Research Agenda for
2019-2022. DESIGN: Multimethod, consensus-building approach by members of the …

Background Age-related immune dysfunction might impair the efficacy of immune
checkpoint inhibitors (ICIs) in older patients. We aimed to evaluate the impact of age on …

Abstract Background and Aims Combination atezolizumab/bevacizumab is the gold
standard for first‐line treatment of unresectable hepatocellular carcinoma (HCC). Our study …

Introduction The real-world effectiveness of combination treatment with cytotoxic
chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor …